Article
Environmental Sciences
Ming Hui Li, Hui Hui Lu, Qi Qi Chen, Yan Jie Lin, Zhan Zeng, Yao Lu, Lu Zhang, Jian Ping Dong, Wei Yi, Yao Xie
Summary: During antiviral therapy, changes in cytokine levels were observed, with PEG-IFN showing significant decreases in certain cytokines and increases in others compared to ETV. PEG-IFN also had higher rates of HBeAg and HBsAg disappearance compared to ETV, indicating better immune control and functional cure.
BIOMEDICAL AND ENVIRONMENTAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Tao Li, Yan Liang, Meng Zhang, Feng Liu, Lixin Zhang, Baohua Yang, Lei Wang
Summary: The study aimed to evaluate the effects of consolidation therapy after discontinuation of nucleoside/nucleotide analogs (NAs) in HBeAg positive chronic hepatitis B (CHB) patients. Results showed that long-term consolidation therapy is generally safe and feasible in these patients, with a preference for a three-year consolidation period in clinical practice.
HEPATOLOGY RESEARCH
(2021)
Review
Medicine, General & Internal
Qian Zhang, Da-Chuan Cai, Peng Hu, Hong Ren
Summary: LLV is defined as persistent or intermittent detectable HBV DNA after 48 weeks of antiviral treatment, and even with long-term therapy, some patients still experience LLV; research on the impact of LLV on clinical outcomes is limited, and there are questions regarding the follow-up treatment for these patients.
CHINESE MEDICAL JOURNAL
(2021)
Article
Gastroenterology & Hepatology
Shun Kaneko, Masayuki Kurosaki, Kento Inada, Sakura Kirino, Yuka Hayakawa, Koji Yamashita, Leona Osawa, Shuhei Sekiguchi, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Nobuharu Tamaki, Yutaka Yasui, Jun Itakura, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi
Summary: This study investigated the virological characteristics of HBcrAg in CHB patients and the factors associated with HCC risk in HBeAg-negative patients. Results showed that higher levels of HBcrAg in HBeAg-negative patients were associated with cirrhosis and higher HBV DNA levels, and were an independent predictive factor for HCC development in patients receiving NA therapy.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Shun Kaneko, Kento Inada, Yuki Tanaka, Shun Ishido, Koji Yamashita, Tsubasa Nobusawa, Hiroaki Matsumoto, Yuka Hayakawa, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Yuka Takahashi, Kaoru Tsuchiya, Hiroyuki Nakanishi, Ryuichi Okamoto, Namiki Izumi
Summary: The aim of this study was to establish a target value of ALT level during NA treatment as a risk marker for HCC. The results showed that patients with ALT <21 IU/L at 1 year after NA initiation had a lower risk of HCC.
HEPATOLOGY RESEARCH
(2023)
Article
Infectious Diseases
Jin Shang, Huan Liu, Qin Wen, Rili M. Ise, You Tu, Lang Bai, Hong Tang
Summary: In this study, nucleos(t)ide analogue therapy with TDF was found to be more effective than LDT during pregnancy in women with chronic hepatitis B, and showed no evidence of renal toxicity. The use of nucleos(t)ide analogue therapy during pregnancy did not significantly impact the long-term physical development and bone development of children.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Der-Yuan Chen, Hsin-Hua Chen, Shih-Hsin Chang, Yi-Ming Chen, Po-Hao Huang, Chia-Wei Hsieh, Joung-Liang Lan, Kuo-Tung Tang
Summary: This study investigated the change of hepatitis B virus (HBV) viral loads and HBV reactivation (HBVr) in rheumatoid arthritis (RA) patients after tapering the dose of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). The results showed that the HBV viral load decreased after the tapering of b/tsDMARDs in RA patients with detectable HBV DNA. Therefore, dose reduction in b/tsDMARDs may be beneficial for RA patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie-Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis
Summary: The study showed that it is safe to discontinue nucleos(t)ide analogues therapy in non-cirrhotic patients with HBeAg-negative chronic hepatitis B. Over a median follow-up of more than 5 years, half of the patients remained without retreatment, with a substantial proportion achieving functional cure.
LIVER INTERNATIONAL
(2021)
Review
Gastroenterology & Hepatology
Beatrice Laupeze, Ventzislav Vassilev, Selim Badur
Summary: Chronic hepatitis B is difficult to cure completely due to various barriers. New therapies, particularly immunotherapies, may offer solutions to address these barriers and improve treatment outcomes.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Medicine, General & Internal
Zaiwei Song, Yi Ma, Dan Jiang, Rongsheng Zhao, Fei Dong
Summary: This study reports the safety and outcomes of rituximab (RTX) administration in diffuse large B cell lymphoma (DLBCL) patients with hepatitis B-related cirrhosis. The findings suggest that, with standardized and valid management strategy, RTX-containing regimens may be a safe option for treating DLBCL patients combined with hepatitis B-related cirrhosis.
FRONTIERS IN MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Man-Fung Yuen, Danny Ka-Ho Wong, Thomas Schluep, Ching-Lung Lai, Carlo Ferrari, Stephen Locarnini, Regina Cheuk-Lam Lo, Robert G. Gish, James Hamilton, Christine Wooddell, Lung Yi Mak, Bruce D. Given
Summary: The study investigated the serological, virological, and histological profiles in chronic HBV patients treated with multiple dose ARC-520. Results showed sustained and profound reductions in viral antigens and HBV RNA, with achievable HBsAg seroclearance. Immune activation was observed in some patients, and HBcAg staining was negative in all biopsied patients.
Article
Gastroenterology & Hepatology
Calvin Q. Pan, Erhei Dai, Zhongping Duan, Guorong Han, Wenjing Zhao, Yuming Wang, Huaihong Zhang, Baoshen Zhu, Hongxiu Jiang, Shuqin Zhang, Xiaohu Zhang, Huaibin Zou, Xiuli Chen, Yu Chen
Summary: The study found that infants exposed to TDF during fetal development had normal physical growth, bone mineral density, and neurodevelopment at 192 weeks of age, demonstrating the long-term safety of maternal TDF therapy for preventing hepatitis B transmission.
Article
Gastroenterology & Hepatology
Sakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, Kento Inada, Koji Yamashita, Shuhei Sekiguchi, Yuka Hayakawa, Leona Osawa, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Namiki Izumi
Summary: In chronic hepatitis B patients, the PAGE-B score can be used for HCC risk assessment, especially at different time points during NA treatment. The predictive ability of mPAGE-B and REACH-B at 2 years after NA treatment is not as good as PAGE-B.
JOURNAL OF VIRAL HEPATITIS
(2021)
Article
Gastroenterology & Hepatology
Jia-Horng Kao, Wen-Juei Jeng, Qin Ning, Tung-Hung Su, Tai-Chung Tseng, Yoshiyuki Ueno, Man-Fung Yuen
Summary: Chronic HBV infection is currently incurable and long-term treatment with NAs can reduce complications, but stopping treatment may lead to virological relapse and adverse outcomes. Close monitoring and personalized follow-up strategies are essential for a safe cessation of NA therapy.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Gastroenterology & Hepatology
Sufang Wei, Meixin Hu, Hongjie Chen, Qiuli Xie, Peng Wang, Hong Li, Jie Peng
Summary: Antiviral treatment with nucleoside/nucleotide analogues (NAs) is effective in suppressing viral replication in HBeAg-negative chronic hepatitis B (CHB) patients with normal or mildly elevated ALT levels. Liver fibrosis is frequently observed in these patients.
BMC GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Yung-Tsung Li, Chun-Jen Liu, Jia-Horng Kao, Li-Feng Lin, Hui-Chu Tu, Chih-Chiang Wang, Po-Hsi Huang, Huei-Ru Cheng, Pei-Jer Chen, Ding-Shinn Chen, Hui-Lin Wu
Summary: MTA1 is a generic RNA-binding protein that regulates gene expression posttranscriptionally by binding to MYC in the cytoplasm, and its interaction with MYC is associated with early recurrence in patients with HBV-HCC.
Letter
Gastroenterology & Hepatology
Tai-Chung Tseng, Tetsuya Hosaka, Jia-Horng Kao
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Grishma Hirode, Bettina E. Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Wong, Wai-Kay Seto, Stijn Van Hees, Margarita Papatheodoridi, Sylvia M. Brakenhoff, Sabela Lens, Hannah S. J. Choi, Rong-Nan Chien, Jordan J. Feld, Xavier Forns, Milan J. Sonneveld, George V. Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Henry L. Y. Chan, Jia-Horng Kao, Yao-Chun Hsu, Markus Cornberg, Wen-Juei Jeng, Harry L. A. Janssen
Summary: Despite improvements in the management of chronic hepatitis B, the risk of cirrhosis and hepatocellular carcinoma remains. The rate of hepatic decompensation is low after discontinuation of nucleos(t)ide analog therapy, but higher in patients with cirrhosis and those who were HBeAg positive at the start of therapy.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Chian-Tzu Huang, Yu-Long Chu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Summary: This study aimed to identify candidates for surgical resection (SR) in Barcelona Clinic Liver Cancer (BCLC) -A/B HCC beyond the Milan criteria with survival benefit. The study found that patients with tumor burden beyond the up-to-7 criteria but within 3 tumors had better overall survival (OS) with SR compared to transarterial chemoembolization (TACE), suggesting that SR should be considered in resectable patients.
Editorial Material
Medicine, General & Internal
Jia-Horng Kao
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Editorial Material
Medicine, General & Internal
Jia-Horng Kao
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Article
Medicine, General & Internal
Tung-Hung Su, Shang-Chin Huang, Chi-Ling Chen, Shih-Jer Hsu, Sih-Han Liao, Chun-Ming Hong, Tai-Chung Tseng, Chen-Hua Liu, Hung-Chih Yang, Yao-Ming Wu, Chun-Jen Liu, Pei-Jer Chen, Jia-Horng Kao
Summary: This study found that preoperative GGT levels ≥ 38 U/L in patients with HBV-related HCC independently predict high risks of HCC recurrence and all-cause mortality. This finding can aid in the clinical diagnosis and management of HCC patients.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2023)
Review
Gastroenterology & Hepatology
Chih-Lin Lin, Jia-Horng Kao
Summary: Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas. Hepatitis B viral load is the most important risk factor for HCC development. Antiviral therapy can reduce the risk of HCC occurrence and serum markers can predict the risk of HCC development.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Yu-Ming Cheng, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao
Summary: The new name and diagnostic criteria of metabolic-associated fatty liver disease (MAFLD) were proposed in 2020. The impact of chronic HBV infection on clinical outcomes of MAFLD was investigated using a Taiwan bio-bank cohort. The study revealed that chronic HBV infection increases the overall risk of liver fibrosis, but protects from atherosclerosis in patients with MAFLD.
Article
Gastroenterology & Hepatology
Young-Suk Lim, Henry L. Y. Chan, Sang Hoon Ahn, Wai Kay Seto, Qin Ning, Kosh Agarwal, Harry L. A. Janssen, Calvin Q. Pan, Wan Long Chuang, Namiki Izumi, Scott Fung, Maurizia Shalimar, Maurizia Brunetto, Aric Josun Hui, Ting-Tsung Chang, Seng Gee Lim, Frida Abramov, John F. Flaherty, Hongyuan Wang, Leland J. Yee, Jia-Horng Kao, Edward Gane, Jinlin Hou, Maria Buti
Summary: This study evaluated the impact of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) on the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). The study found that patients receiving TAF treatment had a lower risk of HCC compared to those receiving TDF treatment, especially in patients without cirrhosis.
Correction
Gastroenterology & Hepatology
Yu-Ming Cheng, Tsung-Han Hsieh, Chia-Chi Wang, Jia-Horng Kao
Meeting Abstract
Gastroenterology & Hepatology
Edo Dongelmans, Grishma Hirode, Bettina Hansen, Chien-Hung Chen, Tung-Hung Su, Wai-Kay Seto, Arno Furquim d'Almeida, Stijn Van Hees, Margarita Papatheodoridi, Sabela Lens, Grace Wong, Sylvia Brakenhoff, Rong-Nan Chien, Jordan J. Feld, Henry Ly Chan, Xavier Forns, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Yao-Chun (Holden) Hsu, Jia-Horng Kao, Markus Cornberg, Milan Sonneveld, Rachel Wen-Juei Jeng, Harry L. A. Janssen
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Grishma Hirode, Bettina Hansen, Chien-Hung Chen, Tung-Hung Su, Grace Wong, Wai-Kay Seto, Arno Furquim d'Almeida, Margarita Papatheodoridi, Sylvia Brakenhoff, Sabela Lens, Hannah S. J. Choi, Stijn Van Hees, Rong-Nan Chien, Jordan J. Feld, Xavier Forns, Milan Sonneveld, George Papatheodoridis, Thomas Vanwolleghem, Man-Fung Yuen, Henry L. Y. Chan, Jia-Horng Kao, Yao-Chun (Holden) Hsu, Markus Cornberg, Rachel Wen-Juei Jeng, Harry L. A. Janssen
JOURNAL OF HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Chung-Feng Huang, Hsing-Tao Kuo, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Lee-Won Chong, Pin-Nan Cheng, Ming-Lun Yeh, Cheng-Yuan Peng, Chien-Yu Cheng, Jee-Fu Huang, Ming-Jong Bair, Chih-Lang Lin, Chi-Chieh Yang, Sih-Ren Wang, Tsai-Yuan Hsieh, Tzong-Hsi Lee, Pei-Lun Lee, Wen-Chih Wu, Chih-Lin Lin, Wei-Wen Su, Shengshun Yang, Chia-Chi Wang, Jui-Ting Hu, Lien-Juei Mou, Chun-Ting Chen, Yi-Hsiang Huang, Chun-Chao Chang, Jia-Sheng Huang, Guei-Ying Chen, Jian-Neng Gao, Chi-Ming Tai, Chun-Jen Liu, Mei-Hsuan Lee, Pei-Chien Tsai, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Chiyi Chen, Kuo-Chih Tseng, Ming-Lung Yu
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Chen-Hua Liu, Chun-Jen Liu, Tung-Hung Su, Tai-Chung Tseng, Pei-Jer Chen, Jia-Horng Kao
Summary: This study analyzed the patient characteristics and clinical performance of retreatment with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C virus (HCV) reinfection after viral clearance. The risk of reinfection was higher in HIV-positive patients than HIV-negative patients. Treating reinfected patients with pangenotypic DAAs showed excellent effectiveness and tolerance, regardless of prior DAA exposure or viral genotypes/subtypes.
ADVANCES IN DIGESTIVE MEDICINE
(2023)